Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NVS vs SGP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVS Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

NVS Overall Winner 6-Pillar Tally: NVS 5 – 0 SGP (1 Tie) Matrix Metrics: NVS 10 – 0 SGP

As of Nov 16, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over SGP (SGP) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVS carries a Unified Composite Score of 43.7/100 (HOLD) at $160.20 (16.1x Forward P/E, 34.0% operating margin), whereas SGP carries 39.3/100 (SELL) at $32.24 (N/M Forward P/E, N/A operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVS vs SGP
NVS NYSE Head-to-Head Winner
Novartis AG
Pharmaceutical Preparations
$160.20
-0.19% 1D
Market Cap $303.1B
TTM Revenue $40.5B
Forward P/E 16.1x
Beta / 30D Vol 0.31β · 27% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 37.0 Fund 37.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 58
RSI-14: 57.7 · SMA20: $159.10 · SMA50: $149.14
SGP US Equity
SGP
Institutional Equity
$32.24
-1.95% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.38β · 70% Vol
Unified Composite Score
39.3 / 100 SELL
Tech 15.0 Fund 45.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.9% over 20 days), RSI 53
RSI-14: 52.7 · SMA20: $32.43 · SMA50: $28.85

6-Pillar Scorecard Institutional Category Breakdown (NVS 5 – 0 SGP)

Columns: Metric · NVS · SGP
1. Valuation Multiples NVS
Forward P/E 16.1x N/M
Trailing P/E 30.6x N/M
PEG Ratio 3.82x N/M
EV / Revenue 7.5x N/M
2. Growth & Scale NVS
Revenue Growth (YoY) +4.7% N/A
Earnings Growth (YoY) -68.8% N/A
TTM Revenue (USD) $40.5B N/A
Market Cap $303.1B N/A
3. Profitability & Quality NVS
Gross Margin 75.2% N/A
Operating Margin 34.0% N/A
Net Profit Margin 17.5% N/A
Return on Equity (ROE) 24.3% N/A
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $17.0B EBITDA N/A
Cash Flow Margin 42.0% EBITDA Mgn N/A
Net Cash / Leverage $19.71 Book/Sh · 24.3% ROE N/A ROE
Dividend Yield 2.95% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 16.9% (6th %ile) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat NVS
OpEx & R&D Intensity 41.2% of Rev ($16.7B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVS (10) vs SGP (0)
Institutional Metric NVS SGP Criterion Row Edge
Market Capitalization
Scale
$303.1B N/A Larger Scale NVS
Trailing P/E Ratio
Valuation
30.6x N/M Lower Multiple NVS
Forward P/E Ratio
Valuation
16.1x N/M Lower Multiple NVS
Revenue Growth (YoY)
Growth
+4.7% N/A Higher Growth NVS
Operating Margin (TTM)
Profitability
34.0% N/A Higher Margin NVS
Net Profit Margin
Profitability
17.5% N/A Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
24.3% N/A Higher ROE NVS
52-Week Range Position
Momentum
78% ($123–$170) 66% ($17–$40) Stronger Trend NVS
Beta / 30D Volatility
Risk Regime
0.31β · 27% Vol 1.38β · 70% Vol Lower Realized Risk NVS
Unified Institutional Score
Composite Signal
43.7 / 100 (HOLD) 39.3 / 100 (SELL) Higher Composite NVS
Trailing 12M Revenue (USD)
Operating Scale
$40.5B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.82x PEG · 7.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGP +27.97 pp
NVS: +6.36% · SGP: +34.33%
3M Horizon SGP +21.11 pp
NVS: +3.66% · SGP: +24.77%
6M Horizon SGP +37.55 pp
NVS: +7.41% · SGP: +44.96%
1Y Horizon SGP +19.7 pp
NVS: +2.42% · SGP: +22.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs SGP. Trailing 12-month operating profitability (NVS 34.0% vs SGP N/A) and valuation multiples (NVS 16.1x vs SGP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.1x
SGP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SGP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $303.1B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published
SGP Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NVS vs SGP Key Questions & Quantitative Answers

As of Nov 16, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over SGP (SGP) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVS carries a Unified Composite Score of 43.7/100 (HOLD) at $160.20 (16.1x Forward P/E, 34.0% operating margin), whereas SGP carries 39.3/100 (SELL) at $32.24 (N/M Forward P/E, N/A operating margin). Technically, NVS sits in a Markup phase (RSI 57.7, UNCLASSIFIED options structure) and SGP sits in a Markup phase (RSI 52.7, UNCLASSIFIED options structure).

NVS leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with SGP at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus N/A for SGP. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGP.

NVS screens cheaper on headline valuation multiples. NVS trades at 16.1x Forward P/E, 30.6x Trailing P/E, 3.82x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas SGP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus SGP (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, SGP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.38β · 70% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.